

PUBLIKATIONSVERZEICHNIS

Univ.-Prof. Dr. med. Johannes Waltenberger, F.E.S.C.
Professor für Innere Medizin, Kardiologie und Angiologie
Medizinische Fakultät der Westfälischen-Wilhelms-Universität Münster
waltenberger@hin.ch
waltenberger@email.de

Publikationen 439 im Web of Science; Hirsch-Index 64, Gesamtzahl der Zitate > 17.200

Originalarbeiten

- 1) Waltenberger J. Der Einfluß des Adrenalins und des Beta-Blockers Nadolol auf die Erythrozyten-Verformbarkeit. Inauguraldissertation. Ruprecht-Karls-Universität Heidelberg, 1990.
<http://www.worldcat.org/oclc/75168075>
- 2) Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, and Heldin C-H. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. *Biochem. Biophys. Res. Commun.* 184: 1311-1316, 1992.
- 3) Waltenberger J, Usuki K, Fellström B, Funa K, and Heldin C-H. Platelet-derived endothelial cell growth factor: Pharmacokinetics, organ distribution and degradation after intravenous administration in rats. *FEBS Lett.* 313: 129-132, 1992.
- 4) Waltenberger J, Lundin L, Öberg K, Wilander E, Miyazono K, Heldin C-H, and Funa K. Involvement of transforming growth factor- β in the formation of fibrotic lesions in carcinoid heart disease. *Am. J. Pathol.* 142: 71-78, 1993.
- 5) Waltenberger J, Miyazono K, Funa K, Wanders A, Fellström B, and Heldin C-H. Transforming growth factor- β and organ transplantation. *Transplant. Proc.* 25: 2038-2040, 1993.
- 6) Wanders A, Akyürek ML, Waltenberger J, Stafberg C, Larsson E, Zhiping R, Funa K, and Fellström B. The impact of ischemia time on chronic vascular rejection in the rat - effects of angiopeptin. *Transplant. Proc.* 25: 2098-2099, 1993.
- 7) Waltenberger J, Wanders A, Fellström B, Miyazono K, Heldin C-H, and Funa K. Induction of transforming growth factor- β during cardiac allograft rejection. *J. Immunol.* 151: 1147-1157, 1993.
- 8) Öberg C, Waltenberger J, Claesson-Welsh L, and Welsh M. Expression of protein tyrosine kinases in islet cells: possible role of the flk-1 receptor for β -cell maturation from duct cells. *Growth Factors* 10: 115-126, 1994.
- 9) Waltenberger J, and Thelin S. Images in cardiovascular medicine. Papillary fibroelastoma as an unusual source of repeated pulmonary embolism. *Circulation* 89: 2433, 1994.
- 10) Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, and Heldin C-H. Different signal transduction properties of *KDR* and *Flt1*, two receptors for vascular endothelial growth factor. *J. Biol. Chem.* 269: 26988-26995, 1994.
- 11) Kovalenko M, Gazit A, Böhmer A, Rorsman C, Heldin C-H, Waltenberger J, Böhmer F-D, and Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse *sis*-transformation. *Cancer Res.* 54: 6106-6114, 1994.
- 12) Wanders A, Akyürek ML, Waltenberger J, Ren ZP, Stafberg C, Funa K, Larsson E, and Fellström B. Ischemia-induced transplant arteriosclerosis in the rat. *Arterioscler. Thromb. Vasc. Biol.* 15: 145-155, 1995.

- 13) Waltenberger J, Mayr U, Frank H, and Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its anti-angiogenic action. *J. Mol. Cell. Cardiol.* 28: 1523-1529, 1996.
- 14) Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, and Risau W. The vascular endothelial growth factor receptor FLT-1 mediates biological activities: Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J. Biol. Chem.* 271: 17629-17634, 1996.
- 15) Waltenberger J, Mayr U, Pentz S, and Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. *Circulation* 94: 1647-1654, 1996.
- 16) Waltenberger J, Akyürek ML, Aurivillius M, Wanders A, Larsson E, Fellström B, and Funa K. Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression. *Arterioscler. Thromb. Vasc. Biol.* 16: 1516-1523, 1996.
- 17) Waltenberger J. Funktion und Regulation von Wachstumsfaktoren in der Gefäßwand. Implikationen für die Therapie kardiovaskulärer Erkrankungen. Habilitationsschrift. Universität Ulm, 1997.
- 18) Fellstrom B, Akyurek ML, Larsson F, Waltenberger J, Wanders A, Funa K. Ischemia induced upregulation of growth factor expression in experimental transplant arteriosclerosis. *Transplant. Proc.* 29: 2558, 1997.
- 19) Torzewski M, Torzewski J, Bowyer D, Waltenberger J, Fitzsimmons C, Hombach V, and Gabbert HE. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell α -actin in early atherosclerotic lesions. *Arterioscler. Thromb. Vasc. Biol.* 17: 2448-2452, 1997.
- 20) Kroll J, and Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. *J. Biol. Chem.* 272: 32521-32527, 1997.
- 21) Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez LS, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, and Gertz SD. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointima formation after balloon angioplasty in swine. *Circulation* 97: 1960-1969, 1998.
- 22) Röckl W, Hecht D, Sztajer H, Meier K, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition with the soluble VEGF receptors 1 and 2. *Exp. Cell Res.* 241: 161-170, 1998.
- 23) Wiecha J, Reineker K, Reitmayer M, Voisard R, Hannekum A, Mattfeldt T, Waltenberger J, and Hombach V. Modulation of Ca^{2+} -activated K^{+} channels in human vascular cells by insulin and basic fibroblast growth factor. *Growth Horm. IGF Res.* 8: 175-181, 1998.
- 24) Torzewski J, Torzewski M, Bowyer DE, Fröhlich, M, Koenig W, Waltenberger J, Fitzsimmons C, Gabbert HE, and Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions in human coronary arteries. *Arterioscler. Thromb. Vasc. Biol.* 18: 1386-1392, 1998.
- 25) Kroll J, and Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). *Biochem. Biophys. Res. Commun.* 252: 743-746, 1998.
- 26) Meyer M, Clauss M, Lepple-Wienhus A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha H-J, and Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling by VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. *EMBO J.* 18: 363-374, 1999.
- 27) Froschermaier SE, Werner D, Leike M, Schneider M, Waltenberger J, and Daniel WG. Enhanced external counterpulsation as a new treatment modality for patients with erectile dysfunction. *Urol. Int.* 61: 168-71, 1999.

- 28) Kranz A, Mattfeldt T, and Waltenberger J. Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. *Int. J. Cancer* 84: 293-298, 1999.
- 29) Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, Fujita D, Gazit A, Hombach V, Levitzki A, and Boehmer F-D. A dual inhibitor of platelet-derived growth factor β -receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. *Circ. Res.* 85: 12-22, 1999.
- 30) Skaletz-Rorowski A, Waltenberger J, Müller JG, Pawlus E, Pinkernell K, and Breithardt G. Protein kinase C mediates basic fibroblast growth factor-induced proliferation through mitogen-activated protein kinase in coronary smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* 19: 1608-1614, 1999.
- 31) Kranz A, Mayr U, Frank H, and Waltenberger J. The coronary endothelium: a target for VEGF. Human coronary artery endothelial cells express functional receptors for VEGF *in vitro* and *in vivo*. *Lab. Invest.* 79: 985-991, 1999.
- 32) Kroll J, and Waltenberger J. A novel function of VEGF-receptor-2/KDR: Rapid release of nitric oxide in response to VEGF-A stimulation of endothelial cells. *Biochem. Biophys. Res. Commun.* 265: 636-639, 1999.
- 33) Kranz A, Rau C, Kochs M, and Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. *J. Mol. Cell. Cardiol.* 32: 65-72, 2000.
- 34) Fishbein I*, Waltenberger J*, Banai S, Rabinovich L, Chorny M, Levitzki A, Gazit A, Huber R, Mayr U, Gertz DS, Golomb G. Local delivery of PDGF receptor-specific tyrphostin inhibits neointimal formation in rats. *Arterioscler. Thromb. Vasc. Biol.* 20: 667-676, 2000.
- 35) Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, and Huot J. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. *J. Biol. Chem.* 275: 10661-10672, 2000.
- 36) Waltenberger J, Lange J, and Kranz A. Vascular endothelial growth factor-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. A potential predictor for the individual capacity to develop collaterals. *Circulation* 102: 185-190, 2000.
- 37) Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, and Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. *Cancer Res.* 60: 5117-5124, 2000.
- 38) Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* 20: 2094-2099, 2000.
- 39) Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of vascular endothelial growth factor receptors causes lung cell apoptosis and emphysema. *J. Clin. Invest.* 106: 1311-1319, 2000.
- 40) Waltenberger J, Kranz A, Beyer M. Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy. *Angiogenesis* 3: 345-351, 2000.
- 41) Böldicke T, Tesar M, Griesel C, Rohde M, Gröne H-J, Waltenberger J, Kollet O, Lapidot T, Yayon A, and Weich H. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34⁺ cells from cord blood. *Stem Cells* 19: 24-36, 2001.

- 42) Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, and Tuder RM. Inhibition of the VEGF receptor KDR combined with chronic hypoxia causes severe pulmonary hypertension with pulmonary endothelial cell proliferation. *FASEB J.* 15: 427-438, 2001.
- 43) Scheidegger P, Weiglhofer W, Suarez S, Console S, Waltenberger J, Pepper MS, Jaussi R, and Ballmer-Hofer K. Signalling properties of a human immunodeficiency virus-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. *Biochem J.* 353: 569-578, 2001.
- 44) Faehling M, Koch ED, Raithel J, Trischler G, Waltenberger J. Ca²⁺-activated K⁺ channels (K_{ca} channels) in human endothelial cells are activated by vascular endothelial growth factor-A. *Int. J. Biochem. Cell Biol.* 33: 337-346, 2001
- 45) Rusnati M, Urbinati C, Musulin B, Ribatti D, Albin A, Noonan D, Waltenberger J, and Presta M. Activation of endothelial cell mitogen activated protein kinase ERK_{1/2} by extracellular HIV-1 Tat protein. *Endothelium* 8: 65-74, 2001.
- 46) Skaletz-Rorowski A, Müller JG, Kroke A, Waltenberger J, Pulawski E, Pinkernell K, and Breithardt G. Lovastatin blocks bFGF-induced MAPK signaling in cSMC via phosphatase inhibition. *Eur. J. Cell Biol.* 80: 207-212, 2001.
- 47) Schneider E, Schmid-Kotsas A, Zhao J, Weidenbach H, Schmid RM, Menke A, Adler G, Waltenberger J, Grünert A, Bachem MG. Identification of mediators stimulating activation, proliferation and matrix synthesis of cultured rat pancreatic stellate cells. *Am J. Physiol. Cell Physiol.* 281: C532-C543, 2001.
- 48) Kirkin V, Mazitschek R, Krishnan J, Steffen A, Mandriota SJ, Waltenberger J, Pepper MS, Giannis A, and Sleeman JP. Characterisation of indolinones which specifically inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 but not VEGFR-2. *Eur. J. Biochem.* 268: 5530-5540, 2001.
- 49) Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J and Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by VEGF receptor-2 / KDR. *J. Biol. Chem.* 277: 3101-3108, 2002.
- 50) Stracke S, Konner K, Friedl R, Keller F, Hombach V, Waltenberger J. Increased expression of TGF- β 1 and IGF-I in inflammatory stenotic lesions in hemodialysis fistulae. *Kidney Int.* 61: 1011-1019, 2002.
- 51) Mayr-Wohlfart U, Waltenberger J, Hausser H, Kessler S, Günther K-P, Puhl W, Brenner R. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. *Bone* 30: 472-477, 2002.
- 52) Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. *J Neurosci.* 22: 6401-6407, 2002.
- 53) Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, John W, Marks JW, Waltenberger J, Thorpe P, and Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. *Proc. Natl. Acad. Sci. U.S.A.* 99: 7866-7871, 2002.
- 54) Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R, Gati I, Kanaan M, Waltenberger J*, Golomb G. Novel PDGF α R antisense encapsulated in polymeric nanospheres for the treatment of restenosis. *Gene Ther.* 9: 1607-1616, 2002. (* Korrespondierender Autor)
- 55) Faehling M, Kroll J, Föhr KJ, Fellbrich G, Mayr U, Trischler G, Waltenberger J. Essential Role of Calcium in Vascular Endothelial Growth Factor-A-induced Signaling: Mechanism of the Antiangiogenic Effect of Carboxyamidotriazole. *FASEB J.* 13: 1805-1807, 2002.
- 56) Gazit A, Yee K, Uecker A, Bohmer FD, Sjoblom T, Ostman A, Waltenberger J, Golomb G, Banai S, Heinrich MC, Levitzki A. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. *Bioorg. Med. Chem. Lett.* 11: 2007-2018, 2003.
- 57) Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM, Waltenberger J*, and Beltinger C. Endothelial progenitor cell culture and differentiation *in vitro*. A methodological

comparison using human umbilical cord blood. *Cardiovasc. Res.* 58: 478-486, 2003. (* Korrespondierender Autor)

- 58) Yilmaz A, Kliche S, Mayr-Beyrle U, Fellbrich G and Waltenberger J. The antiapoptotic role of VEGFR-2 is mediated via inhibition of p38 MAPK. *Biochem. Biophys. Res. Commun.* 306: 730-736, 2003.
- 59) Autiero M*, Waltenberger J*, Communi D*, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimovic D, van Hummelen P, Dehio C, Hicklin D, Persico G, Herbert J-M, Communi D, Shibuya M, Collen D, Conway EM and Carmeliet P. Role of PlGF in *intra-* and *intemolecular* crosstalk between VEGF receptors Flt1 and Flk-1. *Nat. Med.* 9: 936-943, 2003. (* equal contribution, split first authorship)
- 60) von Degenfeld G; Raake P, Kupatt C, Leberherz C, Hinkel R, Gildehaus FJ, Munzing W, Kranz A, Waltenberger J, Simoes M, Schwaiger M, Thein E, Boekstegers P. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. *J. Am. Coll. Cardiol.* 42: 1120-1128, 2003.
- 61) Beil M, Micoulet A, von Wichert G, Paschke S, Walther P, Omary MB, Van Veldhoven PP, Gern U, Wolff-Hieber E, Eggermann J, Waltenberger J, Adler G, Spatz J, Seufferlein T. Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. *Nat. Cell Biol.* 5: 803-811, 2003.
- 62) Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Mönkkönen J, Gao J, Gati I, Golomb G. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon injury in the rat carotid artery, *J. Cardiovasc. Pharmacol.* 42: 671-679, 2003.
- 63) Babiak A, Schumm A-M, Wangler C, Loukas M, Wu J, Dombrowski S, Mattuschek C, Kotzerke J, Dehio C, Waltenberger J. Coordinated activation of VEGFR1 and VEGFR2 represents a potent arteriogenic stimulus leading to enhancement of regional perfusion in a mouse hindlimb model. *Cardiovasc. Res.* 61: 789-795, 2004.
- 64) Urbinati C, Bugatti A, Oreste P, Zappetti G, Waltenberger J, Mitola S, Ribatti D, Presta M, and Rusnati M. Chemically sulfated *Escherichia coli* K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. *FEBS Lett.* 568: 171-177, 2004.
- 65) Agema WRPA, Monraats PS, Zwinderman AH, de Winter RJ, Tio RA, Doevendans PAFM, Waltenberger J, de Maat MPM, Frants RR, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era. *Eur. Heart J.* 25: 1163-1170, 2004.
- 66) Kirkin V, Thiele W, Matzichek R, Rohde K, Fellbrich G, Baumann P, Weich H, Waltenberger J, Giannis A and, Sleeman JP. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. *Int. J. Cancer* 112: 986-993, 2004.
- 67) Friedl R, Li J, Schumacher B, Hanke H, Waltenberger J, Hannekum A, Stracke S. Intimal Hyperplasia and Expression of Transforming Growth Factor-beta1 in Saphenous Veins and Internal Mammary Arteries Before Coronary Artery Surgery. *Ann Thorac Surg.* 78: 1312-1318, 2004.
- 68) Loukas M, Dabrowski MP, Kantoch M, Ruzyllo W, Waltenberger J, Giannikopoulos P. A case report of Noonan's syndrome with pulmonary valvar stenosis and coronary aneurysms. *Med. Sci. Monit.* 10: CS80-83, 2004.
- 69) Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. - 455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. *Thromb. Haemost.* 93: 564-9; 2005.
- 70) Becker PM, Waltenberger J, Yachechko R, Mirzapioazova T, Sham JS, Lee CG, Elias JA, Verin AD. Neuropilin-1 Regulates Vascular Endothelial Growth Factor-Mediated Endothelial Permeability. *Circ. Res.* 96: 1257-65, 2005.

- 71) Reinhardt B, Mertens T, Mayr-Beyrle U, Frank H, Lüske A, Waltenberger J. HCMV-infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF β -receptor. *Cardiovasc. Res.* 67: 151-60, 2005.
- 72) Fiedler J, Leucht F, Waltenberger J, Dehio C, Brenner RE. VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. *Biochem. Biophys. Res. Commun.* 334: 491-9, 2005.
- 73) Morbidelli L, Monici M, Marziliano N, Cogoli A, Fusi F, Waltenberger J, Ziche M. Simulated hypogravity impairs the angiogenic response of endothelium by up-regulating apoptotic signals. *Biochem. Biophys. Res. Commun.* 334: 491-9, 2005.
- 74) Bekkers SCAM, Prenger K, Waltenberger J. Intramyocardial Dissection After Subacute Anterior Wall Myocardial Infarction. *Images in Cardiovascular Medicine. Heart* 91: e54, 2005.
- 75) Monraats PS, Pires NMM, Agema WRP, Zwinderman AH, Schepers A, de Maat MPM, Doevendans PAFM, de Winter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van Vlijmen BJM, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. *Circulation* 112: 2417-25, 2005.
- 76) Weigand M, Hantel P, Kreienberg R, and Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures *in vitro*. *Angiogenesis* 8: 197-204, 2005.
- 77) Monraats PS, Pires NMM, Schepers A, Agema WRP, Boesten LSM, de Vries MR, Zwinderman AH, de Maat MPM, Doevendans PAFM, de Winter RJ, Tio RA, Waltenberger J, 't Hart LM, Frants RR, Quax PHA, van Vlijmen BJM, Havekes LM, van der Laarse A, van der Wall EE, Jukema JW. Tumor Necrosis Factor- α Plays an Important Role in Restenosis Development. *FASEB J.* 19: 1998-2004, 2005.
- 78) Urbinati C, Mitola S, Tanghetti E, Kumar C, Waltenberger J, Ribatti D, Presta M, and Rusnati M. Integrin α V β 3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. *Arterioscler Thromb Vasc Biol.* 25: 2315-20, 2005.
- 79) Rana JS, Monraats PS, Zwinderman AH, de Maat MP, Kastelein JJ, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement. *Thromb Haemost* 94: 892-4, 2005.
- 80) Waltenberger J. Fusion und Privatisierung – Rahmenbedingungen und Chancen. *Lehre und Forschung* 13: 88, 2006.
- 81) Donnini S, Finetti F, Lusini L, Morbidelli L, Cheynier V, Barron D, Williamson G, Waltenberger J and Ziche M. Different effects of Quercetin conjugates on angiogenesis. *Br. J. Nutrition* 95: 1016-23, 2006.
- 82) Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, Zijlstra F, van der Steege G, de Winter RJ, Doevendans PA, Waltenberger J, Wouter Jukema J, Tio R. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. *Pharmacogenet. Genomics* 16: 331-7, 2006.
- 83) Buchwald AB, Kunze C, Waltenberger J, Unterberg-Buchwald C. Transfection of the DNA for the Receptor KDR/flk-1 Attenuates Neointimal Proliferation and Luminal Narrowing in a Coronary Stent Angioplasty Model. *J. Surg. Res.* 136: 120-4, 2006.
- 84) Monraats PS, de Vries F, de Jong LW, Pons D, Sewgobind VD, Zwinderman AH, de Maat MP, 't Hart LM, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Wouter Jukema J. Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention. *Pharmacogenet. Genomics* 16: 747-54, 2006.

- 85) Czepluch FS, Waltenberger J. Monocyte responsiveness towards different arteriogenic stimuli - a functional comparison of various chemoattractants and their combinations. *Thromb. Haemost.* 96; 857-8, 2006.
- 86) Stadler N, Eggermann J, Voo S, Kranz A, Waltenberger J. Smoking-induced monocyte dysfunction is reversed by chronic administration of vitamin C *in vivo*. *Arterioscler. Thromb. Vasc. Biol.* 27:120-6, 2007.
- 87) Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. *Genes Immun.* 8:44-50, 2007.
- 88) Czepluch FS, Bergler A, Waltenberger J. Hypercholesterolaemia impairs monocyte function in CAD patients. *J. Intern. Med.* 261: 201-4, 2007.
- 89) Vainer J, van Ommen V, Maessen J, Geskes G, Lamerichs L, Waltenberger J. Elective high-risk Percutaneous Coronary Interventions supported by Extracorporeal Life Support. *Am. J. Cardiol.* 99: 771-3, 2007.
- 90) Schmidt M, Khan A, Schmidt AM, Heinze B, Hack E, Waltenberger J, Kreienberg R. A novel breast cancer cell line initially established from pleural effusion: Evolution towards a more aggressive phenotype. *Int. J. Oncol.* 30: 565-72, 2007.
- 91) Nacak TG, Alajati A, Leptien K, Fulda C, Weber H, Miki T, Czepluch FS, Waltenberger J, Wieland T, Augustin HG, and Kroll J. The BTB-kelch protein KLEIP controls endothelial migration and sprouting angiogenesis. *Circ. Res.* 100: 1155-63, 2007.
- 92) Czepluch FS, Waltenberger J. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine: relevance to the human situation? *J. Thorac. Cardiovasc. Surg.* 133: 1685-6, 2007.
- 93) Czepluch FS, Olieslagers SJ, Waltenberger J. Monocyte function is severely impaired by the fluorochrome calcein acetomethylester. *Biochem. Biophys. Res. Commun.* 361: 410-3, 2007.
- 94) Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. *Thromb. Haemost.* 98: 1323-8, 2007.
- 95) Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y, Noël A, Waltenberger J, Lapière CM, Nuscgens BV and Lambert CA. VEGF111, a New VEGF-A Isoform Biologically Active and Resistant to Proteolysis is Induced by Genotoxic Agents. *J. Cell Biol.* 179: 1261-73, 2007.
- 96) Tchaikovski V, Fellbrich G, and Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. *Arterioscler. Thromb. Vasc. Biol.* 28: 322-8, 2008.
- 97) Vöö S, Eggermann J, Dunaeva M, Ramakers-van Oosterhoud C, Waltenberger J. Enhanced functional response of CD133⁺ circulating progenitor cells in patients early after acute myocardial infarction. *Eur. Heart J.* 29: 241-50, 2008.
- 98) Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KMJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WRM, Biemond BJ, Tijssen JGP, van Rossum AC, Piek JJ, Zijlstra F. Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. *Catheter Cardiovasc Interv.* 71: 273-81, 2008.
- 99) Stadler N, Stanley N, Heeneman S, Vacata V, Daemen M, Bannon PG, Waltenberger J, and Davies MJ. Accumulation of zinc in human atherosclerotic lesions correlates with calcium levels but does not protect against protein oxidation. *Arterioscler. Thromb. Vasc. Biol.*, 28: 1024-30, 2008.

- 100) Czepluch FS, Waltenberger J. Monocyte function rather than number is a prerequisite for the stimulation of collateral growth. *Atherosclerosis* 196: 485–6, 2008.
- 101) Czepluch FS, Waltenberger J. Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus-eluting and bare-metal stents. *Eur Heart J.* 29:1924-5, 2008.
- 102) Cleutjens KB, Faber BC, Rousch M, van Doorn R, Hackeng TM, Vink C, Geusens P, ten Cate H, Waltenberger J, Tchaikovski V, Lobbes M, Somers V, Sijbers A, Black D, Kitslaar PJ, Daemen MJ. Non-invasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by autoantibody profiling. *J. Clin. Invest.* 118:2979-85, 2008.
- 103) van Golde JM, Ruiter MS, Schaper NC, Vöö S, Waltenberger J, Backes WH, Post MJ, Huijberts MS. Impaired collateral recruitment and outward remodeling in experimental diabetes. *Diabetes* 57:2818-23, 2008.
- 104) Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH and Machein MR. Flt-1 signaling in macrophages promotes glioma growth *in vivo*. *Cancer Res.* 68:7342-51, 2008.
- 105) van der Laan AM, Hirsch A, Nijveldt R, van der Vleuten PA, van der Giessen WJ, Doevendans PA, Waltenberger J, ten Berg JM, Aengevaeren WRM, Zwaginga JJ, Biemond BJ, van Rossum AC, Tijssen JHP, Zijlstra F, Piek JJ. Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. *Neth Heart J.*, 16:436-9, 2008.
- 106) Czepluch FS, Zweigle B, Waltenberger J. Chemotaxis analysis of circulating monocytes in patients with a recent acute coronary syndrome. *Atherosclerosis* 204:304-8, 2009.
- 107) Vöö S, Dunaeva M, Eggermann J, Stadler N, Waltenberger J. Type II diabetes mellitus reduces the function of CD133⁺ progenitor cells in patients with stable coronary artery disease and with acute myocardial infarction. *J. Intern. Med.* 265:238-49, 2009.
- 108) Yetkin E, Waltenberger J. Cathepsin Enzymes and Cystatin C: Do They Play a Role in Positive Arterial Remodeling? *Stroke.* 40:e26-7, 2009.
- 109) Pons D, Monraats PS, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Jukema JW. Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. *Dis. Markers*, 26:75-83, 2009.
- 110) Tchaikovski V, Olieslagers S, Böhmer F-D, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in VEGF resistance of human monocytes. *Circulation*, 120: 150-159, 2009.
- 111) Bekkers SCAM, Backes WH, Kim RJ, Snoep G, Gorgels APM, Lima Passos V, Waltenberger J, Crijns HJGM, Schalla S. Detection and Characteristics of Microvascular Obstruction in Reperfused Acute Myocardial Infarction using an Optimized Protocol for Contrast Enhanced Cardiovascular Magnetic Resonance Imaging. *Eur Radiol*, 19: 2904-2912, 2009.
- 112) Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med.* 361: 1045-57, 2009.
- 113) Dunaeva M, Vöö S, van Oosterhoud C, Waltenberger J. Diabetes mellitus type 2 inhibits monocyte chemotaxis towards the morphogen Sonic hedgehog. *Basic. Res. Cardiol*, 105: 61–71, 2010.
- 114) Hermeling E, Hoeks APG, Winkens MHW, Waltenberger J, Reneman RS, Kroon AA, Reesink KD. Non-invasive assessment of arterial stiffness should discriminate between systolic and diastolic pressure ranges. *Hypertension* 55: 124-30, 2010.

- 115) Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J, dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. *Am Heart J*, 158: 896-901, 2009.
- 116) Morbidelli L, Pyriochou A, Filippi S, Vasileiadis I, Roussos C, Zhou Z, Loutrari H, Waltenberger J, Stössel A, Giannis A, Ziche M, Papapetropoulos A. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. *Am J Physiol Regul Integr Comp Physiol*. 298: R824-32, 2010.
- 117) Monraats PS, Fang Y, Pires NM, Pols HA, Zwinderman AH, de Maat MP, Doevendans PA, Dewinter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van der Laarse A, van der Wall EE, Uitterlinden AG, Jukema JW. Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. *Expert Opin Ther Targets*, 14: 243-51, 2010.
- 118) Schalla S, Bekkers SC, Dennert R, van Suylen RJ, Waltenberger J, Leiner T, Wildberger J, Crijns HJ, Heymans S. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: Comparison of magnetic resonance imaging with right ventricular biopsy? *Eur J Heart Fail*, 12: 227-31, 2010.
- 119) Winkens M, Eerens F, Waltenberger J. Rapid disappearance of a massive iatrogenic haematoma of the left hand following radial coronary angiogram. *Netherlands Heart J*, 18: 212, 2010.
- 120) Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Cohen-Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. *Antiviral Therapy*, 15: 193-201, 2010
- 121) Babiker FA, Lorenzen-Schmidt I, Mokelke E, Vanagt WY, Delhaas T, Waltenberger J, Cleutjens JP and Prinzen FW. Long term protection and mechanism of pacing-induced postconditioning in the heart. *Basic. Res. Cardiol*, 105: 523-33, 2010.
- 122) Kastrati A, Balducelli M, Di Sciascio G, Moccetti T, Bortone AS, Colombo A, Waltenberger J, Hehrlein C. A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. *EuroIntervention*, 5: 976-80, 2010.
- 123) Cosemans JM, van Kruchten R, Olieslagers S, Schurgers LJ, Verheyen FK, Munnix IC, Waltenberger J, Angelillo-Scherrer A, Hoylaerts MF, Carmeliet P, Heemskerk JW. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization.. *J. Thromb. Haemost.* 8: 1797-808, 2010.
- 124) Bekkers SCAM, Smulders MW, Lima Passos V, Leiner T, Waltenberger J, Gorgels APM, Schalla S. Clinical Implications of Microvascular Obstruction and Intramyocardial Haemorrhage in Acute Myocardial Infarction Using Cardiovascular Magnetic Resonance Imaging. *Eur Radiol*. 20: 2572-8, 2010.
- 125) Donners MMPC, Wolfs I, Olieslagers S, Mohammadi-Motahhari Z, Tchaikovski V, Heeneman S, van Buul JD, Caolo V, Molin D, Post MJ, Waltenberger J. Functional interaction of the metalloprotease ADAM10 and Vascular Endothelial Growth Factor Receptor 2 in angiogenesis and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.*, 30: 2188-2195, 2010.
- 126) Gerretsen, S, Kooi ME, Kessels A, Schalla S, Katoh M, van der Geest RJ, Manning WJ, Waltenberger J, van Engelshoven JMA, Botnar RM, Leiner T. Visualization of coronary wall atherosclerosis in asymptomatic subjects and patients with coronary artery disease using magnetic resonance imaging. *PLoS ONE*. 29;5(9). pii: e12998, 2010.
- 127) Czepluch FS, Barrès R, Caidahl K, Krook A, Rickenlund A, Zierath JR, Waltenberger J. Strenuous physical exercise adversely affects monocyte chemotaxis. *Thromb. Haemost.*,105:122-30, 2011.

- 128) Caolo V, van den Akker NMS, Verbruggen S, Donners MMPC, Swennen G, Schulten H, Waltenberger J, Post MJ, Molin DGM. Feed-forward signaling by membrane bound ligand receptor circuit: the case of NOTCH-Delta like 4 in endothelial cells. *J. Biol. Chem.*, 285: 40681-9, 2010.
- 129) Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F; HEBE Investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. *Eur Heart J.* 32: 1736-47, 2010.
- 130) Smid M, Dielis AW, Winkens M, Spronk HM, Van Oerle R, Hamulyák K, Prins MH, Rosing J, Waltenberger JL, Ten Cate H. Thrombin generation in patients with a first acute myocardial infarction. *J. Thromb. Haemost.*, 9: 450-456, 2011
- 131) Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. *EuroIntervention.* 6: 805-12, 2011.
- 132) Pons D, Trompet S, de Craen AJ, Thijssen PE, Quax PH, de Vries MR, Wierda RJ, van den Elsen PJ, Monraats PS, Ewing MM, Heijmans BT, Slagboom PE, Zwinderman AH, Doevendans PA, Tio RA, de Winter RJ, de Maat MP, Iakoubova OA, Sattar N, Shepherd J, Westendorp RG, Jukema JW; PROSPER study group; WOSCOPS study group; GENDER study group. Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. *Heart*, 97: 143-50, 2011
- 133) Czepluch FS, Olieslagers S, van Hulten R, Vöö SA, Waltenberger J. VEGF-A-induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. *Atherosclerosis*, 215: 331-8, 2011.
- 134) Olieslagers S, Pardali E, Tchaikovski V, Ten Dijke P, Waltenberger J. TGF-beta1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. *Cardiovasc Res.* 91: 510-8, 2011.
- 135) Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. *BMC Cancer.* 11: 358, 2011.
- 136) Bekkers SC, Lemmert ME, Passos VL, Muhl C, Schalla S, Wildberger JE, Waltenberger J, Gorgels AP. The relationships between cardiovascular magnetic resonance imaging variables of acute myocardial infarction and both left ventricular dysfunction and immediate postreperfusion ST segment recovery. *J. Electrocardiol* 44: 561-7, 2011.
- 137) Lebedz P, Meiners J, Samol A, Wasmer K, Reinecke H, Waltenberger J, Eckardt L. Electrocardiographic changes during therapeutic hypothermia. *Resuscitation.* 83: 602-6, 2011.
- 138) Versteylen MO, Bekkers SC, Smulders MW, Winkens B, Muhl C, Winkens MH, Leiner T, Waltenberger JL, Kim RJ, Gorgels AP. Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction. *Heart*, 98: 109-15, 2012.
- 139) van den Akker NM, Kolk FF, Jeukens F, Verbruggen S, Gagliardi M, Dullens S, Heschel I, Post MJ, Molin DG, Waltenberger J. Vascular potency of Sus scrofa bone marrow-derived mesenchymal stem cells: a progenitor source of medial but not endothelial cells. *Tissue Eng Part A.* 18: 828-39, 2012.
- 140) Milberg P, Klocke R, Frommeyer G, Quang TH, Dieks K, Stypmann J, Osada N, Kuhlmann M, Fehr M, Milting H, Nikol S, Waltenberger J, Breithardt G, Eckardt L. G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis, angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure. *Basic Res Cardiol.* 106: 995-1008, 2012.

- 141) Samol A, Woetzel F, Barth PJ, Bräuningner A, Waltenberger J, Lebiedz P. A rare cause of fatal right ventricular cardiac decompensation. *Cardiovasc Pathol.*, 21: 515-8, 2012.
- 142) Stadler N, Heeneman S, Vöö S, Stanley N, Giles GI, Gang BP, Croft KD, Mori TA, Vacata V, Daemen MJ, Waltenberger J, Davies MJ. Reduced metal ion concentrations in atherosclerotic plaques from subjects with type 2 diabetes mellitus. *Atherosclerosis.* 222: 512-8, 2012.
- 143) Landeta F, Hoffmeier A, Fuchs M, Scheld H, Maintz D, Stypmann J, Schober O, Kirchhof P, Spieker T, Waltenberger J. Ectopic thyroid mass in the heart. *Lancet.* 379: 1762, 2012.
- 144) van der Weg K, Bekkers SC, Winkens B, Lemmert ME, Schalla S, Crijns HJ, Waltenberger J, Gorgels AP. Evaluation of the electrocardiogram in identifying and quantifying lateral involvement in nonanterior wall infarction using cardiovascular magnetic resonance imaging. *J Electrocardiol.* 45: 478-84, 2012.
- 145) Gerretsen S, Kessels AG, Nelemans PJ, Dijkstra J, Reiber JH, van der Geest RJ, Katoh M, Waltenberger J, van Engelshoven JM, Botnar RM, Kooi ME, Leiner T. Detection of coronary plaques using MR coronary vessel wall imaging: validation of findings with intravascular ultrasound. *Eur Radiol.* 23: 115-24, 2012.
- 146) Mooren FC, Völker K, Klocke R, Nikol S, Waltenberger J, Krüger K. Exercise delays neutrophil apoptosis by a G-CSF dependent mechanism. *J Appl Physiol.* 113: 1082-90, 2012.
- 147) Razlaf P, Pabst D, Mohr M, Kessler T, Wiewrodt R, Stelljes M, Reinecke H, Waltenberger J, Berdel WE, Lebiedz P. Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. *Respir Med.* 106: 1509-16, 2012.
- 148) Wasmer K, Köbe J, Dechering D, Milberg P, Pott C, Vogler J, Stypmann J, Waltenberger J, Mönning G, Breithardt G, Eckardt L. CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. *Clin Res Cardiol.* 102: 139-44, 2012.
- 149) Paul M, Wichter T, Fabritz L, Waltenberger J, Schulze-Bahr E, Kirchhof P. Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. *Herzschrittmacherther Elektrophysiol.* 23: 186-95, 2012.
- 150) Samol A, Masin M, Gellner R, Otte B, Pavenstädt HJ, Ringelstein EB, Reinecke H, Waltenberger J, Kirchhof P. Prevalence of unknown atrial fibrillation in patients with risk factors. *Europace.* 15: 657-62, 2013
- 151) Delcombel R, Janssen L, Vassy R, Gammons M, Haddad O, Richard B, Letourneur D, Bates D, Hendricks C, Waltenberger J, Starzec A, Sounni NE, Noël A, Deroanne C, Lambert C, Colige A. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. *Angiogenesis.* 16: 353-71, 2013.
- 152) Landeta F, von dem Bussche E, Ritter M, Boentert K, Waltenberger J, Stypmann J. Elevated left ventricular end-diastolic pressure favours closure of foramen ovale. *Acta Cardiol.* 67: 701-6, 2012.
- 153) Pabst D, Römer S, Samol A, Kümpers P, Waltenberger J, Lebiedz P. Predictors and outcome of early-onset pneumonia after out-of-hospital cardiac arrest. *Respir Care.* 58: 1514-20, 2013.
- 154) Idelevich EA, Pogoda CA, Ballhausen B, Wüllenweber J, Eckardt L, Baumgartner H, Waltenberger J, Peters G, Becker K. Pacemaker Lead Infection and Related Bacteremia Caused by Normal and Small Colony Variant Phenotypes of *Bacillus licheniformis*. *J Med Microbiol.* 62: 940-4, 2013.
- 155) Afzali D, Erren M, Pavenstädt HJ, Vollert JO, Hertel S, Waltenberger J, Reinecke H, Lebiedz P. Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. *Clin Res Cardiol.* 102: 755-63, 2013.
- 156) Konings J, Govers-Riemslog JW, Spronk HM, Waltenberger JL, Ten Cate H. Activation of the contact system in patients with a first acute myocardial infarction. *Thromb Res.* 132: 138-42, 2013.

- 157) Hoefler IE, Sels JW, Jukema JW, Bergheanu S, Biessen E, McClellan E, Daemen M, Doevendans P, de Groot P, Hillaert M, Horsman S, Ilhan M, Kuiper J, Pijls N, Redekop K, van der Spek P, Stubbs A, van de Veer E, Waltenberger J, van Zonneveld AJ, Pasterkamp G. Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. *Clin Res Cardiol.* 102: 847-56, 2013.
- 158) Guo H-F, Li X, Parker MW, Waltenberger J, Becker PM, Vander Kooi CW. Mechanistic Basis for the Potent Anti-angiogenic Activity of Semaphorin 3F. *Biochemistry* 52: 7551-8, 2013.
- 159) Kim J, Eligehausen S, Stehling M, Nikol S, Ko K, Waltenberger J, Klocke R. Generation of functional endothelial-like cells from adult mouse germline-derived pluripotent stem cells. *Biochem Biophys Res Commun.* 443: 700-5, 2013
- 160) Sels JW, Rutten B, van Holten T, Hillaert MA, Waltenberger J, Pijls NH, Pasterkamp G, de Groot PG, Roest M. The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease. *PLoS One* 8:e83198, 2013.
- 161) Krüger K, Klocke R, Kloster J, Nikol S, Waltenberger J, Mooren FC. Activity of daily living is associated with circulating CD34+/KDR+ cells and granulocyte colony-stimulating factor levels in patients after myocardial infarction. *J Appl Physiol.* 116: 532-7, 2014.
- 162) Lebiez P, Knickel L, Engelbertz C, Lüders F, Gebauer K, Berdel WE, Waltenberger J, Reinecke H. Impact of preexisting chronic kidney disease on acute and long-term outcome of critically ill patients on a medical intensive care unit. *J Nephrol.* 27: 73-80, 2014.
- 163) Sivri N, Yetkin E, Tekin GO, Yalta K, Waltenberger J. Anticoagulation in Patients With Left Ventricular Systolic Dysfunction and Sinus Rhythm: When? *Clin Appl Thromb Hemost.* 20: 729-34, 2014.
- 164) Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF121/rGel fusion toxin. *J Control Release.* 180: 1-9, 2014.
- 165) Waltenberger J, Gelissen M, Bekkers SC, Vainer J, van Ommen V, Eerens F, Ruiters A, Holthuijsen A, Cuesta P, Strauven R, Mokelke E, Gorgels A, Prinzen FW. Clinical Pacing Post-Conditioning During Revascularization After AMI. Results of the PROTECT study. *JACC Cardiovasc Imaging,* 7: 620-6, 2014.
- 166) Rutten B, Tersteeg C, Vrijenhoek JE, van Holten TC, Elsenberg EH, Mak-Nienhuis EM, de Borst GJ, Jukema JW, Pijls NH, Waltenberger J, van Zonneveld AJ, Moll FL, McClellan E, Stubbs A, Pasterkamp G, Hoefler I, de Groot PG, Roest M. Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques. *PLoS One.* 9: e105019, 2014.
- 167) Yetkin E, Tchaikovski V, Erdil N, Alan S, Waltenberger J. Increased expression of cystatin C and transforming growth factor β -1 in calcific aortic valves. *Int J Cardiol.* 176: 1252-4, 2014.
- 168) Reinhardt B, Godfrey R, Fellbrich G, Frank H, Lüske A, Mertens T, and Waltenberger J. Human cytomegalovirus infection impairs endothelial cell chemotaxis by disturbing VEGF signaling and actin-polymerization. *Cardiovasc. Res.,* 104: 315-25, 2014.
- 169) Loeffen R, van Oerle R, de Groot PG, Waltenberger J, Crijns HJ, Spronk HM, Ten Cate H. Increased factor XIa levels in patients with a first acute myocardial infarction: The introduction of a new thrombin generation based factor XIa assay. *Thromb Res.* 134:1328-34, 2014.
- 170) Florian A, Ludwig A, Engelen M, Waltenberger J, Rösch S, Sechtem U, Yilmaz A. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. *J Cardiovasc Magn Reson.* 16: 81, 2014.
- 171) Heermann P, Hedderich DM, Paul M, Schülke C, Kroeger J, Baeßler B, Wichter T, Maintz D, Waltenberger J, Heindel W, Bunck AC. Biventricular myocardial strain analysis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) using cardiovascular magnetic resonance feature tracking. *J Cardiovasc Magn Reson.* 16: 75, 2014.

- 172) Samol A, Kaese S, Bloch J, Görlich D, Peters G, Waltenberger J, Baumgartner H, Reinecke H, Lebedz P. Infective endocarditis on ICU: risk factors, outcome and long-term follow-up. *Infection*. 43: 287-95, 2015.
- 173) Delewi R, van der Laan AM, Robbers LF, Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, Tio RA, Waltenberger J, Ten Berg JM, Doevendans PA, Gehlmann HR, van Rossum AC, Piek JJ, Zijlstra F; on behalf of the HEBE investigators. Long term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarction. *Heart*. 101: 363-8, 2015.
- 174) Yetkin E, Topal E, Erguzel N, Senen K, Heper G, Waltenberger J. Diabetes Mellitus and female gender are the Strongest Predictors of Poor Collateral Vessel Development in Patients with Severe Coronary Artery Stenosis. *Angiogenesis*. 18: 201-7, 2015.
- 175) Everding S, Römer S, Bohn A, Holz E, Lieder F, Baumgart P, Luyen M, Waltenberger J, Lebedz P. Clinical practice of systemic lysis in prehospital resuscitation: Success and complication rates. *Med Klin Intensivmed Notfmed*. 110; 445-51, 2015.
- 176) Waltenberger J, Brachmann J, van der Heyden J, Richardt G, Fröbert O, Seige M, Erglis A, Dewilde W, Winkens M, Hegeler-Molkewehrum C, Klein N, Hoffmann S. Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: Twelve-month results of the BIOFLOW-III Registry. *Eurointervention*. 11: 1106-10, 2016.
- 177) Schalla S, Jaarsma C, Bekkers SC, Waltenberger J, Dennert R, Crijns HJ, Wildberger J, Heymans S, Brunner-La Rocca HP. Right ventricular function in dilated cardiomyopathy and ischemic heart disease: assessment with non-invasive imaging. *Neth Heart J*. 23: 232-40, 2015.
- 178) Tchaikovski V, Tchaikovski S, Olieslagers S, Waltenberger J. Monocyte dysfunction as a previously unrecognized pathophysiologically relevant component of hyperlipidemic ApoE-/- mice contributing to atherogenesis and impaired arteriogenesis. *Int. J. Cardiol*. 190: 214-6, 2015.
- 179) Florian A, Ludwig A, Stubbe-Dräger B, Boentert M, Young P, Waltenberger J, Rösch S, Sechtem U and Yilmaz A. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. *J Cardiovasc Magn Reson*. 17: 40, 2015. doi: 10.1186/s12968-015-0145-x.
- 180) Selvaraj D, Gangadharan V, Michalski CW, Kurejova M, Stösser S, Srivastava K, Schweizerhof M, Waltenberger J, Ferrara N, Heppenstall P, Shibuya M, Augustin HG and Kuner R. A functional role for VEGFR1 expressed in peripheral sensory neurons in cancer pain. *Cancer Cell*. 27: 780-96, 2015.
- 181) Florian A, Rösch S, Bietenbeck M, Engelen M, Stypmann J, Waltenberger J, Sechtem U, Yilmaz A. Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study. *Eur Heart J Cardiovasc Imaging*. 17: 326-33, 2015.
- 182) Beer K, Rieckmann N, Ertl M, Sumaski L, Zeidler T, Arolt V, Haverkamp W, Waltenberger J, Müller-Nordhorn J, Ströhle A. Assessment and follow-up of suicidal ideation when screening for depression in hospitalized coronary heart disease patients – development of a protocol. *Eur J Pers Cent Healthc*. 3: xxx-xxx, 2015.
- 183) Dunaeva M, van Oosterhout C, Waltenberger J. Expression of Hedgehog signaling molecules in human atherosclerotic lesions: An autopsy study. *Int J Cardiol*. 201: 462-4, 2015.
- 184) Rutten B, Roest M, McClellan EA, Sels, Stubbs A, Jukema JW, Doevendans PA, Waltenberger J, van Zonneveld AJ, Pasterkamp G, de Groot PG and Hofer IE. Platelet density per monocyte predicts adverse cardiac events in patients after percutaneous coronary intervention. *Thromb Haemost* 115; 353-60, 2016.
- 185) Breuckmann F, Remberg F, Böse D, Lichtenberg M, Kümpers P, Pavenstädt H, Waltenberger J, Fischer D. Guideline-conforming timing of invasive management in troponin-positive or high-risk ACS without persistent ST-segment elevation in German chest pain units : Urban university maximum care vs. rural regional primary care. *Herz*. 41: 151-158, 2016.

- 186) Burgers LT, McClellan EA, Hoefler IE, Pasterkamp G, Jukema JW, Horsman S, Pijls NHJ, Waltenberger J, Hillaert MA, Stubbs AC, Severens JL, Redekop WK. Treatment variation in stent choice in patients with stable or unstable coronary artery disease. *Neth Heart J.* 24: 110-9, 2016.
- 187) Becker S, Florian A, Patrascu A, Rösch S, Waltenberger J, Sechtem U, Schwab M, Schaeffeler E, Yilmaz A. Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. *J Cardiovasc Magn Reson.* 18: 25, 2016.
- 188) Vainer J, Habets JHM, Schalla S, Lousberg AHP, de Pont CDJM, Vöö SA, Brans BT, Hoorntje JCA, Waltenberger J. Cardiac shockwave therapy in patients with end-stage coronary artery disease and chronic refractory angina pectoris improves regional myocardial perfusion and reduces ischemia-related symptoms. *Neth Heart J.* 24: 343-349, 2016.
- 189) Er F, Dahlem KM, Nia AM, Erdmann E, Waltenberger J, Hellmich M, Kuhr K, Le MT, Herrfurth T, Taghiyev Z, Biesenbach E, Yüksel D, Eran-Ergöknil A, Vanezi M, Caglayan E, Gassanov N. Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction. The BETA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial. *J Am Coll Cardiol Cardiovasc Interv.* 9: 231-40, 2016.
- 190) Fischer D, Remberg F, Böse D, Lichtenberg M, Kümpers P, Lebedz P, Pavenstädt HJ, Waltenberger J, Breuckmann F. How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities. *Eur J Med Res.* 21: 11, 2016.
- 191) Breuckmann F, Olligs J, Hinrichs L, Koopmann M, Lichtenberg M, Böse D, Fischer D, Eckardt L, Waltenberger J, Garvey JL. Coronary Artery Calcium as an Independent Surrogate Marker in the Risk Assessment of Patients With Atrial Fibrillation and an Intermediate Pretest Likelihood for Coronary Artery Disease Admitted to a German Chest Pain Unit. *Clin Cardiol.* 39:157-64, 2016.
- 192) Becker S, Florian A, Patrascu A, Rösch S, Waltenberger J, Sechtem U, Schwab M, Schaeffeler E, Yilmaz A. Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. *J Cardiovasc Magn Reson.* 18: 25, 2016.
- 193) Breuckmann F, Remberg F, Böse D, Waltenberger J, Fischer D, Rassaf T. On- versus off-hour care for patients with non-ST-segment elevation myocardial infarction in Germany: Exemplary results within the chest pain unit concept. *Herz.* 41: 725-731, 2016.
- 194) Samol A, Gönes M, Zumhagen S, Bruns HJ, Paul M, Vahlhaus C, Waltenberger J, Schulze-Bahr E, Eckardt L, Mönning G. Improved Clinical Risk Stratification in Patients with Long QT Syndrome? Novel Insights from Multi-Channel ECGs. *PLoS One.* 11: e0158085, 2016.
- 195) Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. *PLoS One.* 11: e0160871, 2016.
- 196) Lanier V, Gillespie C, Leffers M, Daley-Brown D, Milner J, Lipsey C, Webb N, Anderson LM, Newman G, Waltenberger J, Gonzalez-Perez RR. Leptin-induced transphosphorylation of vascular endothelial growth factor receptor increases Notch and stimulates endothelial cell angiogenic transformation. *Int J Biochem Cell Biol.* 79: 139–50, 2016.
- 197) Reers S, Agdirlioglu T, Kellner M, Borowski M, Thiele H, Waltenberger J, Reppel M. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. *Eur J Med Res.* 21: 41, 2016.
- 198) Pardali E, Schmitz T, Borgscheiper A, Iking J, Stegger L, Waltenberger J. Cryopreservation of primary human monocytes does not negatively affect their functionality or their ability to be labelled with radionuclides. Basis for molecular imaging and cell therapy. *EJNMMI Research,* 6: 77, 2016.

- 199) Kuhlmann SL, Tschorn M, Arolt V, Beer K, Brandt J, Grosse L, Haverkamp W, Müller-Nordhorn J, Rieckmann N, Waltenberger J, Warnke K, Hellweg R, Ströhle A. Serum brain-derived neurotrophic factor and depressive symptoms in coronary heart disease patients: Role of cognitive functions. *Psychoneuroendocrinology*. 79: 175-176, 2017.
- 200) Rother S, Samsonov SA, Moeller S, Schnabelrauch M, Rademann J, Blaszkiewicz J, Köhling S, Waltenberger J, Pisabarro MT, Scharnweber D, Hintze V. Sulfated Hyaluronan Alters Endothelial Cell Activation In Vitro by Controlling the Biological Activity of the Angiogenic Factors Vascular Endothelial Growth Factor-A and Tissue Inhibitor of Metalloproteinase-3. *ACS Appl Mater Interfaces*. 9: 9539-9550, 2017.
- 201) Kuhlmann SL, Tschorn M, Arolt V, Beer K, Brandt J, Grosse L, Haverkamp W, Müller-Nordhorn J, Rieckmann N, Waltenberger J, Warnke K, Hellweg R, Ströhle A. Serum brain-derived neurotrophic factor and stability of depressive symptoms in coronary heart disease patients: A prospective study. *Psychoneuroendocrinology*. 77: 196-202, 2017.
- 202) Haitjema S, Meddens CA, van der Laan SW, Kofink D, Harakalova M, Tragante V, Foroughi Asl H, van Setten J, Brandt MM, Bis JC, O'Donnell C, Cheng C, Hofer IE, Waltenberger J, Biessen E, Jukema JW, Doevendans PA, Nieuwenhuis EE, Erdmann J, Björkegren JL, Pasterkamp G, Asselbergs FW, den Ruijter HM, Mokry M. Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization. *Circ Cardiovasc Genet*. 10. pii: e001664, 2017.
- 203) Hosseinkhani B, van den Akker N, D'Haen J, Gagliardi M, Struys T, Lambrichts I, Waltenberger J, Nelissen I, Hooyberghs J, Molin DGM, Michiels L. Direct detection of nano-scale extracellular vesicles derived from inflammation-triggered endothelial cells using surface plasmon resonance. *Nanomedicine*. 13: 1663-1671, 2017
- 204) Shomanova Z, Florian A, Bietenbeck M, Waltenberger J, Sechtem U, Yilmaz A. Diagnostic value of global myocardial perfusion reserve assessment based on coronary sinus flow measurements using cardiovascular magnetic resonance in addition to myocardial stress perfusion imaging. *Eur Heart J Cardiovasc Imaging*. 18: 851-859, 2017.
- 205) Tschorn M, Rieckmann N, Arolt V, Beer K, Haverkamp W, Martus P, Waltenberger J, Müller-Nordhorn J, Ströhle A. [Diagnostic Accuracy of German Depression Screenings in Patients with Coronary Heart Disease]. *Psychiatr Prax*. 2017 Apr 3. doi: 10.1055/s-0042-123434.
- 206) Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C, Bonarjee V, Larsen AI, May AE, Empen K, Chorianopoulos E, Tebbe U, Waltenberger J, Mahrholdt H, Ritter B, Pirr J, Fischer D, Korf-Klingebiel M, Arseniev L, Heuft HG, Brinckmann JE, Messinger D, Hertenstein B, Ganser A, Katus HA, Felix SB, Gawaz MP, Dickstein K, Schultheiss HP, Ladage D, Greulich S, Bauersachs J. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. *Eur Heart J*. 38: 2936-294, 2017.
- 207) Rother S, Galiazzo VD, Kilian D, Fiebig KM, Becher J, Moeller S, Hempel U, Schnabelrauch M, Waltenberger J, Scharnweber D, Hintze V. Hyaluronan/Collagen Hydrogels with Sulfated Hyaluronan for Improved Repair of Vascularized Tissue Tune the Binding of Proteins and Promote Endothelial Cell Growth. *Macromol Biosci*. 17: 201, 2017. doi: 10.1002/mabi.201700154. [Epub ahead of print]
- 208) Waltenberger J, Schöne-Seifert B, Friedrich DR, Alt-Epping B, Besthorn M, Dutzmann J, Ertl G, Fateh-Moghadam B, Israel CW, Maase A. Verantwortlicher Umgang mit ICDs. Stellungnahme der Deutschen Gesellschaft für Kardiologie und ihrer Schwester-Gesellschaften. *Kardiologe*. 11: 383–397, 2017.
- 209) Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N Engl J Med*. 377: 1513-1524, 2017.
- 210) Keustermans GC, Kofink D, Eikendal A, de Jager W, Meerding J, Nuboer R, Waltenberger J, Kraaijeveld AO, Jukema JW, Sels JW, Garssen J, Prakken BJ, Asselbergs FW, Kalkhoven E, Hofer

IE, Pasterkamp G, Schipper HS. Monocyte gene expression in childhood obesity is associated with obesity and complexity of atherosclerosis in adults. *Sci Rep.* 7: 16826, 2017.

- 211) Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiecz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeyer B, Krug U. Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. *PLoS One.* 13: e0190802, 2018.
- 212) Koopmann M, Hinrichs L, Olligs J, Lichtenberg M, Eckardt L, Böse D, Möhlenkamp S, Waltenberger J, Breuckmann F. Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit. *Eur J Med Res.* 23:6, 2018.
- 213) Tjaden K, Adam C, Goodfrey R, Peter J, Hanley PJ, Pardali E and Waltenberger J. Low density lipoprotein interferes with intracellular signaling of monocytes resulting in impaired chemotaxis and enhanced chemokinesis. *Int. J Cardiol.* 255:160-165, 2018.
- 214) Bertling A, Fender AC, Schüngel L, Rumpf M, Mergemeier K, Geißler G, Sibrowski W, Kelsch R, Waltenberger J, Jakubowski JA, Kehrel BE. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. *J Thromb Haemost.* 16: 1089-1098, 2018.
- 215) Yetkin E, Ileri M, Waltenberger J. Ecchymosis: A Novel Sign in Patients with Varicose Veins. *Clin Hemorheol Microcirc.* 68: 413-419, 2018.
- 216) Pardali E, Makowski LM, Leffers M, Borgscheiper A, Waltenberger J. BMP-2 induces human mononuclear cell chemotaxis and adhesion and modulates monocyte-to-macrophage differentiation. *J Cell Mol Med.* 55: 5429-5438, 2018.
- 217) Weyergang A, Fremstedal AS, Skarpen E, Peng Q, Mohamedal KA, Eng MS, Cheung LH, Rosenblum MG, Waltenberger J, Berg K. Light-enhanced VEGF₁₂₁/rGel: A tumor targeted modality with vascular and immune-mediated efficacy. *J Control Release.* 288: 161-172, 2018.
- 218) Dorenkamp M, Müller JP, Kallipatti Shanmuganathan S, Schulten H, Müller N, Löffler I, Müller UA, Wolf G, Böhmer F-D, Godfrey R and Waltenberger J. Hyperglycaemia-induced methylglyoxal accumulation potentiates VEGF resistance of diabetic monocytes through the aberrant activation of tyrosine phosphatase SHP-2/SRC kinase signalling axis. *SCIENTIFIC REPORTS.* 8: 14684ff, 2018.
- 219) Reers S, Karanatsios G, Borowski M, Kellner M, Reppel M, Waltenberger J. Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. *Eur J Med Res.* 2018 23: 49, 2018.
- 220) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med.* 379: 2097-2107, 2018. doi: 10.1056/NEJMoa1801174.
- 221) Hornung J, Kuhlmann SL, Radzimanowski M, Jörgens S, Haverkamp W, Martus P, Ströhle A, Waltenberger J, Arolt V, Müller-Nordhorn J, Rieckmann N. Depressive symptoms and health care within 30 days after discharge from a cardiac hospital unit. *Gen Hosp Psychiatry.* 56: 19-27, 2018.
- 222) De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P, ETNA-AF-Europe investigators. Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. *J Cardiovasc Med (Hagerstown).* 20: 97-104, 2019.
- 223) Hornung J, Kuhlmann SL, Radzimanowski M, Jörgens S, Haverkamp W, Martus P, Ströhle A, Waltenberger J, Arolt V, Müller-Nordhorn J, Rieckmann N. Depressive symptoms and health care

within 30 days after discharge from a cardiac hospital unit: Response letter to the editor. *Gen Hosp Psychiatry*. 62: 100-101, 2020.

- 224) Sohrabi Y, Lagache SMM, Schnack L, Godfrey R, Kahles F, Bruemmer D, Waltenberger J, Findeisen HM. mTOR-Dependent Oxidative Stress Regulates oxLDL-Induced Trained Innate Immunity in Human Monocytes. *Front Immunol*. 9: 3155, 2019.
- 225) Schnack L, Sohrabi Y, Lagache SMM, Kahles F, Bruemmer D, Waltenberger J, Findeisen HM. Mechanisms of Trained Innate Immunity in oxLDL Primed Human Coronary Smooth Muscle Cells. *Front Immunol*. 10: 13, 2019.
- 226) Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, Brugs J, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Paré G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. *Circ Genom Precis Med*. 12: 20002470, 2019.
- 227) Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, Van der Harst P, Tardif JC, Sattar N, Lang CC, Paré G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW. Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data. *Circ Genom Precis Med*. 12: e002471, 2019.
- 228) Waltenberger J, Brachmann J, van der Heyden J, Richardt G, Fröbert O, Seige M, Friedrich G, Erglis A, Winkens M, Hegeler-Molkewehrum C, Neef M, Hoffmann S; BIOFLOW-III Investigators. Five-year

results of the BIOFLOW-III Registry: Real-world experience with a biodegradable polymer sirolimus-eluting stent. *Cardiovasc Revasc Med*. 21: 63-69, 2020.

- 229) Stalling P, Engelbertz C, Lüders F, Meyborg M, Gebauer K, Waltenberger J, Reinecke H, Freisinger E. Unmet medical needs in Intermittent Claudication with Diabetes and Coronary Artery Disease - a 'real-world' analysis on 21,197 PAD patients. *Clin Cardiol*. 42: 629-626, 2019.
- 230) Kuhlmann SL, Arolt V, Haverkamp W, Ströhle A, Waltenberger J, Müller-Nordhorn J, Rieckmann N. [Attitudes towards depression and treatment options in patients with coronary heart disease]. *Nervenarzt*. 90: 938-940, 2019
- 231) Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol*. 7: 618-628, 2019. Erratum in: *Lancet Diabetes Endocrinol*. 7(9): e21, 2019
- 232) De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). *BMC Cardiovasc Disord*. 19: 165, 2019.
- 233) Kentgen M, Varghese J, Samol A, Waltenberger J, Dugas M. Common Data Elements for Acute Coronary Syndrome: Analysis Based on the Unified Medical Language System. *JMIR Med Inform*. 7: e14107, 2019.
- 234) Kuhlmann SL, Arolt V, Haverkamp W, Martus P, Ströhle A, Waltenberger J, Rieckmann N, Müller-Nordhorn J. Prevalence, 12-Month Prognosis, and Clinical Management Need of Depression in Coronary Heart Disease Patients: A Prospective Cohort Study. *Psychother Psychosom*. 88: 300-311, 2019.
- 235) Hemling P, Zibrova D, Strutz J, Sohrabi Y, Desoye G, Schulten H, Findeisen H, Heller R, Godfrey R and Waltenberger J. Hyperglycemia-induced endothelial dysfunction is alleviated by thioredoxin mimetic peptides through the restoration of VEGFR-2-induced responses and improved cell survival. *Int. J. Cardiol*. 308: 73-81, 2020.
- 236) Hohls JK, Beer K, Arolt V, Haverkamp W, Kuhlmann SL, Martus P, Waltenberger J, Rieckmann N, Müller-Nordhorn J, Ströhle A. Association between heart-focused anxiety, depressive symptoms, health behaviors and healthcare utilization in patients with coronary heart disease. *J Psychosom Res*. 131: 109958, 2020.
- 237) Sohrabi Y, Sonntag GVH, Braun LC, Lagache SMM, Liebmann M, Klotz L, Godfrey R, Kahles F, Waltenberger J, Findeisen HM. LXR Activation Induces a Proinflammatory Trained Innate Immunity-Phenotype in Human Monocytes. *Front Immunol*. 11: 353, 2020.
- 238) Yetkin E, Yalta K, Waltenberger J. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation. *Neth Heart J*. 28: 437-438, 2020.
- 239) Mahmoodi BK, Tragante V, Kleber ME, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado GE, Eriksson N, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasjärvi P, Lenzini PA, Levin D, Lyytikäinen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Wilson Tang WH, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James S, Mordi IR, Teren A, Bergmeijer TO, Body SC, Bots M, Burkhardt R, Cooper-DeHoff RM, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagström E, Hazen SL, Held C, Hofer IE, Hovingh GK, Johnson JA, Kaczor MP, Kähönen M, Klungel OH, Laurikka JO, Lehtimäki T, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR, Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang CC, Cameron VA, Åkerblom A, Pare G, März W, Samani NJ, Hingorani AD, Ten Berg JM, Wallentin L, Asselbergs FW, Patel RS.

Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. *Circulation*. 142: 546-555, 2020.

- 240) Sohrabi Y, Lagache SMM, Voges VC, Semo D, Sonntag G, Hanemann I, Kahles F, Waltenberger J, Findeisen HM. OxLDL-mediated immunologic memory in endothelial cells. *J Mol Cell Cardiol*. 146:121-132, 2020.
- 241) de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P, ETNA-AF-Europe investigators. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: One year follow up of the prospective observational ETNA-AF-Europe study. *Eur Heart J Cardiovasc Pharmacother*. 7: f30-f39, 2021.
- 242) Brandt J, Warnke K, Jörgens S, Arolt V, Beer K, Domschke K, Haverkamp W, Kuhlmann SL, Müller-Nordhorn J, Rieckmann N, Schwarte K, Ströhle A, Tschorn M, Waltenberger J, Grosse L. Association of FKBP5 genotype with depressive symptoms in patients with coronary heart disease: a prospective study. *J Neural Transm* 127: 1651-1662, 2020.
- 243) Zhang H, Bredewold EOW, Vreeken D, Duijs JMGJ, de Boer HC, Kraaijeveld AO, Jukema JW, Pijls NH, Waltenberger J, Biessen EAL, van der Veer EP, van Zonneveld AJ, van Gils JM. Prediction Power on Cardiovascular Disease of Neuroimmune Guidance Cues Expression by Peripheral Blood Monocytes Determined by Machine-Learning Methods. *Int J Mol Sci*. 21(17):6364, 2020.
- 244) Warnke K, Brandt J, Jörgens S, Arolt V, Beer K, Domschke K, Haverkamp W, Kuhlmann SL, Müller-Nordhorn J, Rieckmann N, Schwarte K, Ströhle A, Tschorn M, Waltenberger J, Grosse L. Association of 5-HTTLPR/rs25531 with depressive symptoms in patients with coronary heart disease: A prospective study. *J Affect Disord*. 277: 531-539, 2020.
- 245) Toelg R, Slagboom T, Waltenberger J, Lefèvre T, Saito S, Kandzari DE, Koolen J, Richardt G. Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent. *Catheter Cardiovasc Interv*. 2020 Sep 5. doi: 10.1002/ccd.29254. Online ahead of print. PMID: 32890442.
- 246) Tschorn M, Kuhlmann SL, Rieckmann N, Beer K, Grosse L, Arolt V, Waltenberger J, Haverkamp W, Müller-Nordhorn J, Hellweg R, Ströhle A. Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease. *Acta Neuropsychiatr*. 33: 22-30, 2021.
- 247) Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. *Diabetes Care*. 2021 Mar 15;dc202842. doi: 10.2337/dc20-2842. Online ahead of print. PMID: 33722880
- 248) Makowski L-M, Leffers M, Waltenberger J, Pardali E. Transforming growth factor-b1 signalling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus. *J Cell Mol Med*. 25(11): 5316-5325, 2021.

Begutachtete und eingeladene Übersichtsartikel

- 1) Hombach V, Waltenberger J, Voisard R, und Höher M. Rezidivstenose nach Koronarangioplastie. Klinische, zellbiologische und molekulare Aspekte. *Z. Kardiol*. 84:5-21, 1995.
- 2) Torzewski J, Bowyer D, Waltenberger J, and Fitzsimmons C. Processes in atherogenesis: complement activation. *Atherosclerosis* 132:129-136, 1997.

- 3) Waltenberger J. Current Perspectives: Modulation of growth factor action. Implications for the treatment of cardiovascular diseases. *Circulation* 96:4083-4095, 1997.
- 4) Kroll J, und Waltenberger J. Regulation der Endothelfunktion und der Angiogenese durch den Vaskulären Endothelialen Wachstumsfaktor-A (VEGF-A). *Z. Kardiol.* 89: 206-218, 2000.
- 5) Waltenberger J. Gentechnologie und Molekularbiologie in der Kardiologie: Update 2000. *Journal für Kardiologie* 7:246-251, 2000.
- 6) Kroll J, and Waltenberger J. Variants of the angiogenic factor vascular endothelial growth factor VEGF. *Expert Opin. Ther. Pat.* 10:981-983, 2000.
- 7) Waltenberger J. Gentherapie bei koronarer Herzkrankheit. Möglichkeiten und Grenzen einer therapeutischen Induktion von Kollateralen. [Gene therapy for coronary artery disease. Perspectives and limitations of the therapeutic induction of a collateral circulation.] *Hämostaseologie* 20:162-166, 2000.
- 8) Waltenberger J. Impaired collateral development in diabetes: Potential cellular mechanisms and therapeutic implications. *Cardiovasc. Res.* 49:554-560, 2001.
- 9) Waltenberger J. Pathophysiologische Grundlagen des akuten Koronarsyndroms. *Herz* 26 (Suppl. 1): 2-8, 2001.
- 10) Waltenberger J. Förderung der Kollateralenbildung: Funktion und Regulation von Wachstumsfaktoren in der Gefäßwand. *Z. Kardiol.* 90 (Suppl 4), 2001.
- 11) Waltenberger J, Jehle PM, Engele J, Kühl M, Wedlich D, and Reinshagen M. Wachstumsfaktor-Modulation als therapeutisches Prinzip. *Deutsches Ärzteblatt* 98:B2909-B2913, 2001.
- 12) Waltenberger J, Babiak A, und Lange J. Störung der Monozytenfunktion bei Diabetes mellitus (Typ 1 und 2) – Molekulare Basis und funktionelle Konsequenzen. *Hämostaseologie* 21: 171-175, 2001.
- 13) Kliche S, and Waltenberger J. VEGF receptor signaling and endothelial function. *IUBMB Life* 52:1-6, 2001.
- 14) Waltenberger J. Wachstumsfaktoren zur Angiogeneese – Kollateralentwicklung, *Cardioews* 10: 44, 25. Oktober 2001.
- 15) Waltenberger J. Vaskuläre Dysfunktion beim Diabetes mellitus: Gestörte Regulationsmechanismen der Entwicklung von Kollateralgefäßen. *MedReport* 43: 6, 2001.
- 16) Waltenberger J. Die Monozytenmigration: Ein Parameter für eine gestörte kardiovaskuläre RepARATION? *CardioNews* 5(5):14, 2002.
- 17) Waltenberger J. Therapie mit Wachstumsfaktoren? *CardioNews* 11: 16, 29. November 2002.
- 18) Waltenberger J. Therapeutic vascular growth in myocardial and peripheral ischemia. *E-journal of Cardiology Practice*, Vol. 2, Nr. 11, 2003.
- 19) Waltenberger J. Therapeutic angiogenesis/arteriogenesis in myocardial and peripheral ischemia. *Angiogenesis* 6: 348-9, 2003
- 20) Luft A, und Waltenberger J. Neurokardiologische Akutmedizin. *Dtsch. Med. Wochenschr.* 129: 151-156, 2004.
- 21) Waltenberger J. Growth factor signal transduction defects in the cardiovascular system. *Cardiovasc. Res.* 65: 574-580, 2005.
- 22) Waltenberger J. Coronary Vascular Destruction and Restructuring after Myocardial Infarction: Its role for Myocardial Healing. *Nova Acta Leopoldina NF* 92, 343: 55-60, 2005.
- 23) Waltenberger J. Wachstumsfaktoren im kardiovaskulären System. *MedReport* 46: 3, 2006.

- 24) Waltenberger J. New Horizons in Diabetes Therapy: The angiogenesis paradox in diabetes: Description of the problem and presentation of a unifying hypothesis. *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry* 7: 87-93, 2007.
- 25) Yetkin E, and Waltenberger J. Novel Insights into an Old Controversy: Is Coronary Artery Ectasia a Variant of Coronary Atherosclerosis? *Clin. Res. Cardiol.* 96: 331-9, 2007.
- 26) Waltenberger J. Stress testing at the cellular and molecular level to unravel cellular dysfunction and growth factor signal transduction defects. What Molecular Cell Biology can learn from Cardiology. *Thromb. Haemost.* 98: 975-979, 2007.
- 27) Waltenberger J. Novel Insights into an Old Controversy: Is Coronary Artery Ectasia a Variant of Coronary Atherosclerosis? Letter to the editor – Response. *Clin. Res. Cardiol.* 96: 832, 2007.
- 28) Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. *Int. J. Cardiol.* 135: 4-13, 2009.
- 29) Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. *Biochem Soc Trans.* 37: 1167-70, 2009.
- 30) Bekkers SCAM, Yazdani SK, Virmani R, Waltenberger J. Microvascular Obstruction: Underlying Pathophysiology and Clinical Diagnosis. *J. Am. Coll. Cardiol.* 55: 1649-1660, 2010.
- 31) Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefler I, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoğlu L. Stabilisation of atherosclerotic plaques. Position Paper of the European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology. *Thromb Haemost.* 106: 1-19, 2011.
- 32) Pardali E, Waltenberger J. Monocyte function and trafficking in cardiovascular disease. *Thromb Haemost.* 108: 804-11, 2012.
- 33) Paul M, Wichter T, Fabritz L, Waltenberger J, Schulze-Bahr E, Kirchhof P. Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. *Herzschrittmacherther Elektrophysiol.* 23: 186-95, 2012.
- 34) Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefler I, Jauhiainen S, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoğlu L; ESC Working Group of Atherosclerosis and Vascular Biology. Stabilization of atherosclerotic plaques: an update. *Eur Heart J.* 34:3251-8, 2013.
- 35) Armstrong EJ, Waltenberger J, Rogers JH. Percutaneous Coronary Intervention in Patients with Diabetes: Current Concepts and Future Directions. *J Diabetes Sci Technol.* 8: 581-9, 2014.
- 36) Tjaden K, Pardali E, Waltenberger J. Hypercholesterolemia induces vascular cell dysfunction: molecular basis for atherosclerosis. *Austin J Vasc Med.*, 2: 1011-9, 2015.
- 37) Waltenberger J. Wenn Medizintechnik einen würdevollen Tod verhindert – Defibrillatoren am Lebensende abschalten. Eine Form der Sterbehilfe? *PLEXUS.* 24: 4-5, 2016.
- 38) Dunaeva M, Waltenberger J. Hh signaling in regeneration of the ischemic heart. *Cell Mol Life Sci.* 74: 3481-3490, 2017.
- 39) Ten Berg JM, Zwart B, van 't Hof AWJ, Liem A, Waltenberger J, de Winter RJ, Jukema JW. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome: Practical lessons from a review. *Neth Heart J.* 25: 655-663, 2017.
- 40) Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe

ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*. 21: 425-532, 2018.

- 41) Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insight into the pathogenesis of coronary artery ectasia. *Cardiovasc Pathol*. 35: 37-47, 2018.
- 42) Zwart B, Ten Berg JM, van 't Hof AW, Tonino PAL, Appelman Y, Liem AH, Arslan F, Waltenberger J, Jukema JW, de Winter RJ, Damman P. Indications for an early invasive strategy in NSTEMI-ACS patients. *Neth Heart J*. 28: 131-135, 2020.
- 43) Waltenberger J. Frontiers in Cardiovascular Biomedicine 2020. *Eur Heart J*. 41: 910-910, 2020.
- 44) Evans PC, Ed Rainger G, Mason JC, Guzik TJ, Osto E, Stamataki Z, Neil D, Hoefer IE, Fragiadaki M, Waltenberger J, Weber C, Bochaton-Piallat ML, Bäck M. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. *Cardiovasc Res*. 116: 2177-2184, 2020.
- 45) Dweck MR, Maurovich-Horvat P, Leiner T, Cosyns B, Fayad ZA, Gijzen FJH, Van der Heiden K, Kooi ME, Maehara A, Muller JE, Newby DE, Narula J, Pontone G, Regar E, Serruys PW, van der Steen AFW, Stone PH, Waltenberger JL, Yuan C, Evans PC, Lutgens E, Wentzel JJ, Bäck M. Contemporary rationale for non-invasive imaging of adverse coronary plaque features to identify the vulnerable patient: a Position Paper from the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 21: 1177-1183, 2020.
- 46) Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vlahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat ML, Evans PC. ENDOTHELIAL FUNCTION IN CARDIOVASCULAR PRECISION MEDICINE: A POSITION PAPER ON BEHALF OF THE EUROPEAN SOCIETY OF CARDIOLOGY. *Cardiovasc Res*. 117: 29-42, 2021.
- 47) Evans P, Wojta J, Hoefer IE, Waltenberger J, Guzik T, Badimon L, Weber C. THE YEAR IN BASIC VASCULAR BIOLOGY RESEARCH: FROM MECHANORECEPTORS AND NETS TO SMARTPHONE DATA AND OMICS. *Cardiovasc Res*. 2021 Mar 21:cvab105. doi: 10.1093/cvr/cvab105. Online ahead of print. PMID: 33744925

Editorials

- 1) Waltenberger J. Therapeutic angiogenesis in the heart using peptide growth factors: Angiogenesis research entering clinical trials. (Editorial/News and Views). *Angiogenesis* 2:115-117, 1998.
- 2) Post MJ, Waltenberger J. Modulation of growth factor action in the cardiovascular system. *Cardiovasc. Res*. 65: 547-549, 2005.
- 3) Waltenberger J. Regenerative Cardiology: There are various ways to prosper. *Thromb. Haemost.* 94: 695-6, 2005.
- 4) Post MJ, Waltenberger J. ACE inhibitors and statins for bone marrow failure following myocardial infarction? *Cardiovasc. Res*. 70: 1-2, 2006.

- 5) Post MJ, Waltenberger J. Small is beautiful: a miniature stent model. *Arterioscler. Thromb. Vasc. Biol.* 27: 701-2, 2007.
- 6) Waltenberger J, Vainer J. PCI comes to age as age increasingly comes to PCI. *Netherlands Heart J.* 16: 115-6, 2008.
- 7) Waltenberger J. Limits to Growth of native collateral vessels: Just one mouse CLIC away from unlimited collateral perfusion? *Circ. Res.* 105: 9-11, 2009.
- 8) Fadini GP, Madeddu P, Waltenberger J, Fiorina P. Vascular Stem and Progenitor Cells in Diabetic Complications. *Exp Diabetes Res.* 2012: 580343, 2012.
- 9) Waltenberger J, Pardali E. Oiling vascular growth: adipokines can induce (pathological) angiogenesis by using the VEGF/VEGFR system. *Cardiovasc Res.* 96: 220-2, 2012.
- 10) Ozkan J, Waltenberger J. Pioneer: Johannes Waltenberger, MD, FESC. *Circulation* 07/2012; 126: F25-F28, 2012.
- 11) Waltenberger J. Chronische Herzinsuffizienz bei geriatrischen Patienten. *Geriatric-Report.* 1: 24, 2014.
- 12) Häussinger D, Waltenberger J. European Journal of Medical Research reviewer acknowledgment 2014. *Eur J Med Res.* 20: 19-23, 2015.
- 13) Häussinger D, Waltenberger J. Thanks to all those who reviewed for *European Journal of Medical Research* in 2015. *Eur J Med Res.* DOI: 10.1186/s40001-016-0200-6, 2016.
- 14) Waltenberger J. Chronic refractory angina pectoris: Recent progress and remaining challenges. *Eur Heart J.* 38: 2556-2558, 2017.
- 15) Waltenberger J, Pearson J. Scientists on the Spot: The past, present, and future of the Council on Basic Cardiovascular Science. *Cardiovascular Research.* 114: e74–e75, 2018.
- 16) Ferdinandy P, Koller Á, Weber C, Waltenberger J. Postponement of Frontiers in Cardiovascular Biomedicine (FCVB) 2020 due to COVID-19: a look forward to 2021. *Cardiovasc Res.* 116: e78-e81, 2020.

Supplement-Beiträge, Buchbeiträge, Letter to the Editor

- 1) Waltenberger J. Transforming growth factor- β induction in carcinoid heart disease. In: *Growth factors and the cardiovascular system.* Cummins P (ed.), Kluwer Academic Publishers, Norwell, pp. 311-320, 1993.
- 2) Wanders A, and Waltenberger J. Transplantation models of accelerated arteriosclerosis and their use for morphological and molecular analysis. In: *New pathogenic aspects of arteriosclerosis emphasizing transplantation atheroarteritis. Abhandlungen der Rheinisch-Westfälischen Akademie der Wissenschaften,* Hauss WH, Wissler RW, Bauch H-J (eds.), Bd. 93, Westdeutscher Verlag, Opladen, pp. 95-108, 1994.
- 3) Waltenberger J, Böhmer F, Mayr U, Heldin C-H, Hombach V und Levitzki A. Charakterisierung von Rezeptor-Tyrosin-Kinase-Hemmern: Selektivität und molekulare Basis für eine Therapie der Restenose. In: *Endothelfunktion und Arteriosklerose,* Heinle H, Schulte H, Breddin K. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 268-274, 1994.

- 4) Fellström BC, Akyürek L, Dimény E, Kaijser M, Larsson E, Waltenberger J, Wanders A, and Wahlberg J. Chronic vascular rejection (CVR). *Mitteilungen der Arbeitsgemeinschaft für Klinische Nephrologie* 24: 41-53, 1995.
- 5) Wiecha J, Reineker K, Reitmayer M, Voisard R, Baur R, Hannekum A, Mattfeldt T, Kochs M, Hombach V, und Waltenberger J. Einfluß von Insulin auf Ca^{2+} -aktivierte K^+ -Kanäle in humanen vaskulären Zellen. In: *Arteriosklerose zerebraler Gefäße*, Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 30-34, 1995.
- 6) Wiecha J, Pu J, Waltenberger J, Mayr U, Trischler G, Weismüller P, und Hombach V. Hypoxie, Azidose und Glukosemangel erhöhen Ca^{2+} -aktivierte K^+ Ströme in kultivierten humanen Endothelzellen. In: *Arteriosklerose zerebraler Gefäße*, Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 242-246, 1995.
- 7) Gürtler R, Hombach V, und Waltenberger J. Hemmung der VEGF-induzierbaren Proliferation des Endothels unter Hyperglykämie. In: *Arteriosklerose zerebraler Gefäße*, Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 247-252, 1995.
- 8) Torzewski J, Waltenberger J, Bowyer D, und Hombach V. Komplementsystem in der Atherogenese. In: *Endokrine und zellbiologische Aspekte der Arteriosklerose*. Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 52-56, 1996.
- 9) Waltenberger J, Huber R, Mayr U, Pentz S, und Hombach V. Die Rolle des Vascular Endothelial Growth Factor VEGF in der Hypoxie-induzierten Neovaskularisation des Myokards. Synergie zwischen Ligand und Rezeptor. In: *Endokrine und zellbiologische Aspekte der Arteriosklerose*. Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 179-183, 1996.
- 10) Schlösser A, Waltenberger J, und Hombach V. Modulation der VEGF-abhängigen Endothelfunktion durch oxidiertes LDL. In: *Endokrine und zellbiologische Aspekte der Arteriosklerose*. Heinle H, Schulte H, Kaffarnik H. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 302-307, 1996.
- 11) Waltenberger J, Frank H, Mayr U, Weich H, und Hombach V. Lösliche VEGF-Rezeptoren als funktionelle VEGF-Antagonisten. Implikationen für eine Antiangiogenese im arteriosklerotischen Plaque. In: *Adhäsionsmoleküle, Zytokine und Apoptose bei der Gefäßumgestaltung*. Heinle H, Schulte H, Siegel G. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 56-61, 1997.
- 12) Waltenberger J, Huber R, Frank H, und Hombach V. Hemmung der PDGF-abhängigen Aktivierung glatter Gefäßmuskelzellen durch das Tyrphostin AG1295. Spezifische Rezeptor-Inaktivierung als molekularer Ansatz zur Prävention der Restenose. In: *Adhäsionsmoleküle, Zytokine und Apoptose bei der Gefäßumgestaltung*. Heinle H, Schulte H, Siegel G. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 178-182, 1997.
- 13) Waltenberger J. Perspektiven der Genterapie bei der Behandlung der koronaren Herzkrankheit. In: Leschke, Schoebel, Strauer (Hrsg.) Chronische Myokardischämie bei koronarer Herzkrankheit. Eine Standortbestimmung. *Z. Kardiol.* 87 (Suppl. 2): 152-156, 1998.
- 14) Waltenberger J, und Hombach V. Therapie der akuten Myokardischämie. In: *Vaskuläre Medizin*. Nawroth PP, und Lasch HG (Hrsg.), Uni-Med Verlag, Bremen, S. 235-244, 1999.
- 15) Waltenberger J, Huber R, Frank H, Hombach V, Banai S, und Levitzki A. Das Tyrphostin AG1295, ein selektiver PDGF-Rezeptor-Inhibitor, hemmt die Aktivierung glatter Gefäßmuskelzellen *in vitro* und *in vivo* sowie die Neointima-Bildung *in vivo*. In: *Die Bedeutung von Proteoglykanen, Lipoproteinen und Lipasen für die Atherogenese*. Heinle H, Schulte H, Siegel G. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 101-105, 1999.
- 16) Kroll J, und Waltenberger J. Der VEGF Rezeptor-2 (KDR) beeinflusst die VEGF-abhängige Regulation des Gefäßtonus und die VEGF-abhängige Angiogenese über die Induktion der Expression der endothelialen NO-Synthase (eNOS) und der induzierbaren NO-Synthase (iNOS) in Endothelzellen. In:

Atherogenese und metabolisches Syndrom. Heinle H, Schulte H, Hanefeld M. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen S. 105-108, 2000.

- 17) Kranz A, Mayr U, Frank H, und Waltenberger J. Das koronare Endothel exprimiert funktionelle VEGF-Rezeptoren *in vivo* und *in vitro*. In: *Atherogenese und metabolisches Syndrom*. Heinle H, Schulte H, Hanefeld M. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 113-118, 2000.
- 18) Waltenberger J, Kroll J, Frank H, Mayr U, Hombach V, Uecker A, Böhmer FD, Gazit A, und Levitzki A. Das Tyrphostin PP1/AGL1872 hemmt die Migration und Proliferation glatter Muskelzellen durch die duale Inhibierung des PDGF β -Rezeptors und des Onkogens *Src*. Eine neue Strategie zur Verhinderung der Restenose. In: *Atherogenese und metabolisches Syndrom*. Heinle H, Schulte H, Hanefeld M. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 124-127, 2000.
- 19) Waltenberger J. Molekularbiologische Techniken und Gentherapie. In: *Lehrbuch der interventionellen Kardiologie, Angiologie und Kardiovaskularchirurgie*. Hombach V (Hrsg.), Schattauer, Stuttgart - New York, S.279-291, 2000.
- 20) Waltenberger J. Molekularbiologie der Arteriosklerose: Pathogenese und Mediatoren. In: *Endovaskuläre versus konventionelle Gefäßchirurgie*. Eckstein H-H, Sunder-Plassmann L (Hrsg.), Steinkopff, Darmstadt, 2001.
- 21) Lange J, Kranz A, Waltenberger J. Abgeschwächte chemotaktische Stimulierbarkeit von Monozyten durch Vascular Endothelial Growth Factor-A (VEGF-A) bei Patienten mit Diabetes mellitus. Ein potentieller Prädiktor der individuellen Fähigkeit zur Ausbildung von Kollateralen. In: *Determinanten und Beeinflussung der Plaqueentwicklung*, Heinle H, Schulte H, Hanefeld M. (Hrsg.), Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, S. 90-95, 2001.
- 22) Waltenberger J, and Hombach V. Therapeutic angiogenesis for the heart. In: *The New Angiotherapy*. Fan T-PD, and Auerbach R (Hrsg.), Humana Press Inc., Totowa, NJ, 279-293, 2002.
- 23) Waltenberger J. Molekularbiologie der Arteriosklerose: Pathogenese und Mediatoren. In: *Endovaskuläre versus konventionelle Gefäßchirurgie – Zwischenbilanz und Standortbestimmung*. Eckstein H-H, und Sunder-Plassmann L (Hrsg.), Steinkopff, Darmstadt, S. 3-5, 2001.
- 24) Waltenberger J. Molekularbiologische Prinzipien in Diagnostik und Therapie kardiovaskulärer Erkrankungen. In: *Handbuch der kardiovaskulären Medizin*. Hombach V (Hrsg.), Schattauer, Stuttgart - New York, in press, 2002.
- 26) Waltenberger J. Weit fortgeschrittene Arteriosklerose. Angiologische Sicht: Gentechnische Ansätze. In: *Interventionelle Gefäßtherapie*. Vallbracht C, Roth F-J, und Strauss AL (Hrsg.), Steinkopff, Darmstadt, S.357-362, 2002.
- 27) Waltenberger J. Biologische Rezidivprophylaxe. Kardiologische Sicht. In: *Interventionelle Gefäßtherapie*. Vallbracht C, Roth F-J, und Strauss AL (Hrsg.), Steinkopff, Darmstadt, S.404-409, 2002.
- 28) Waltenberger J. Molecular imaging of the endothelial cell. *Horm Metab Res* 39(3): Cover, 2007
- 29) Tchaikovski V, and Waltenberger J. Angiogenesis and arteriogenesis in diabetes mellitus: Signal transduction defects as the molecular basis of vascular cell dysfunction. In: *Therapeutic Neovascularization: Quo vadis?* Deindl E, Kupatt C (eds.), Springer, Heidelberg, S. 33-73, 2007.
- 30) Yetkin E, Waltenberger J. Re: Is Varicocele Associated With Underlying Venous Abnormalities? Varicocele and the Prostatic Venous Plexus H. Sakamoto and Y. Ogawa. *J Urol* 2008; 180: 1427-1431. *J Urol*. 2009 Feb 24. [Epub ahead of print]
- 31) Waltenberger J. Wet AMD: anti-VEGF treatments in the elderly population. *Br. J. Cardiol.* 16 (Suppl.2): S11-S13, 2009.
- 32) Tchaikovski V, and Waltenberger, J. Negative predictors of collateral formation: Evidence based on novel functional and mechanistic data. Published as an E-letter to *European Heart Journal* on 9 September 2009, available at <http://eurheartj.oxfordjournals.org/cgi/eletters/30/7/840>

- 33) Pardali E, Godfrey R, Waltenberger J. VEGF Signaling in Normal and Tumor Angiogenesis. In: Tumor Angiogenesis Regulators. Editors: Rueda BR and Gonzalez-Perez RR. ISBN 978-1-57808-785-3. CRC/Science Publishers, Enfield, NH, USA. www.scipub.net, p1 – p36, 2013.

Patente

United States Patent No. 6,358,954, filed on November 9, 1999, issued on March 19, 2002. PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME. Levitzki A, Gazit A, Banai S, Gertz DS, Golomb G, Boehmer FD, Waltenberger J.

Waltenberger JL, Czepluch FS, Eggermann J: Cellular stress testing in the cardiovascular system.

Pub. No.: WO/2009/061191; International Application No.: PCT/NL2008/050703;

filed on November 6, 2008; issued on May 14, 2009;

<http://www.wipo.int/pctdb/en/wo.jsp?WO=2009061191&IA=NL2008050703&DISPLAY>

<https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009061191>

Coburg, 6. Juni 2021

A handwritten signature in blue ink, appearing to read 'Johannes Waltenberger', is written over a faint, light blue circular watermark or stamp.